The effect of sulforaphane on depression in women with PCOS

Evaluating the effect of sulforaphane supplementation in women with Polycystic ovary syndrome (PCOS) on depression, insulin resistance, and lipid profile change

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N144

Enrollment

Registered

2022-06-26

Start date

2022-08-23

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severity of depression. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Women with PCOS take sulforaphane 15 mg twice a day for 12 weeks. Intervention 2: Control group: Women with PCOS take placebo twice a day for 12 weeks.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Diagnosis of PCOS according to Rotterdam Mild to moderate depression 18-40 years old BMI = or > 25 High blood fat Disruption of Glucose tolerance test

Exclusion criteria

Exclusion criteria: Smoking Lactation or gestation Metabolic or thyroid dysfunction Hyperprolactinemia Hypercortisolemia Severe depression CNS drugs used such as antidepressants or anxiolytics Insulin administration Uncontrolled blood glucose level Intense physical activity History of severe stress Emotional failure or hospitalization in recent past History of mental health problems in first-degree relatives

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 4, 8, & 12. Method of measurement: By Hamilton Depression Rating Scale (HDRS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026